Congress Updates in NSCLC: Advancing Care Through Emerging Immunotherapy Evidence

NOV 12, 202624 MIN

Description

Please visit answersincme.com/PXD860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ticiana Leal, MD. In this activity, an expert in thoracic oncology discusses the latest data for immunotherapy-based combination regimens in the treatment of non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for immunotherapy (ICI)-based regimens in the treatment of non–small-cell lung cancer (NSCLC), including ICI + tyrosine kinase inhibitor (TKI) combinations; Assess how emerging data on immunotherapy-based regimens may influence the evolving treatment landscape for patients with NSCLC; and Incorporate the latest evidence on approved and emerging ICI-based regimens into practical NSCLC management across disease settings.